Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

Abstract Background The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to...

Full description

Bibliographic Details
Main Authors: Molly A. Taylor, Adina M. Hughes, Josephine Walton, Anna M. L. Coenen-Stass, Lukasz Magiera, Lorraine Mooney, Sigourney Bell, Anna D. Staniszewska, Linda C. Sandin, Simon T. Barry, Amanda Watkins, Larissa S. Carnevalli, Elizabeth L. Hardaker
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
CT-26
MC38
4 T1
Syngeneic
Immune checkpoint blockade
Online Access:http://link.springer.com/article/10.1186/s40425-019-0794-7

Internet

http://link.springer.com/article/10.1186/s40425-019-0794-7

Similar Items